%0 Journal Article
%A Navarro-Ruíz, Eva
%A Peña, M Ángeles
%A Dahma, Zaid
%A Álvarez Álvarez, Covadonga
%A Torrado Salmerón, Carlos Félix
%A Torre Iglesias, Paloma Marina De La
%T Multiparticulate Systems of Meloxicam for Colonic Administration in Cancer or Autoimmune Diseases
%D 2022
%@ 1999-4923
%U https://hdl.handle.net/20.500.14352/92180
%X The aim of this research is the development of new colonic release systems of meloxicam (MLX) a non-steroidal anti-inflammatory drug (NSAIDs) with pH and time-dependent vehicles for cancer or autoimmune diseases. The colon has a higher pH than the rest of the gastrointestinal tract (GIT) and this can be used as a modified release strategy. Eudragit® polymers are the most widely used synthetic products in the design of colonic release formulations because they might offer mucoadhesiveness and pH-dependent release. Colonic delivery systems produced with pH-dependent and permeable polymers (FS-30D) or with pH-independent and low permeability polymers (NM-30D), must dissolve at a pH range of 6.0–7.0 to delay the release of the drug and prevent degradation in the GIT, before reaching the colon. The conditions prepared to simulate a gastrointestinal transit showed the CNM multiparticulate system, composed of Eudragit® NM and cellulose, as the best release option for MLX with a more sustained release with respect to the other formulations. CNM formulation followed Higuchi and First-order release kinetics, thus MLX release was controlled by a combination of diffusion and polymers swelling/eroding processes.
%~